Antibiotic price formulation in Tanzania: evidence from national regulatory import permit data 2010-2016

This study analyzes Tanzania's 2010–2016 antibiotic import data to reveal that pricing is systematically influenced by formulation type, supplier origin, and naming practices, highlighting the need for import-level monitoring to guide procurement and stewardship policies in low- and middle-income countries.

The Gist

Imagine Tanzania's medicine market as a massive, bustling supermarket, but instead of buying cereal or soap, the government and hospitals are buying life-saving antibiotics. This study acts like a detective looking at the receipts from the back door of that supermarket—the "import permits"—to figure out exactly how much these medicines cost before they even hit the shelves.

The researchers looked at 7 years of receipts (from 2010 to 2016) to answer a simple question: Why do prices for the exact same antibiotic vary so wildly?

Here is the story of what they found, broken down with some everyday analogies:

1. The "Receipt" vs. The "Shelf Price"

Most people think medicine prices are set by the pharmacy down the street. But this study looked at the upstream prices—the cost when the medicine first arrives in the country from a foreign factory.

• The Analogy: Think of it like buying a car. The study didn't look at the sticker price at the local dealership (which includes taxes, dealer fees, and profit). Instead, they looked at the price the dealership paid the factory in another country. This is the "true cost" before anyone adds their markup.

2. The "Big Three" and the "Long Tail"

The study found that Tanzania imports a huge variety of antibiotics, but a tiny few dominate the market.

• The Analogy: Imagine a pizza shop that sells 100 different toppings. But 90% of the orders are just for Pepperoni (Amoxicillin) and Pepperoni & Cheese (Amoxicillin-Clavulanate). The rest of the toppings (like rare mushrooms or exotic spices) are ordered very rarely.
• The Finding: Because so many people are buying these two specific antibiotics, the market is heavily focused on them. India was the main "factory" supplying these pizzas, providing nearly half of all the orders.

3. The "Liquid vs. Pill" Price Gap

One of the biggest surprises was the difference between pills (oral) and injections (parenteral).

• The Analogy: You might think a pill is cheaper because it's just a tablet. But in this market, injections were consistently more expensive and more chaotic in price.
• Why? It's like the difference between buying a bottle of water and a bottle of water that has been sterilized, sealed in a sterile vial, and requires a nurse to administer. The study found that while pill prices slowly went down over the years, injection prices jumped up and down like a rollercoaster. This suggests that getting injections into the country is a much more complicated, "bumpy" process than getting pills.

4. The "Name Brand" vs. "Generic" Confusion

Usually, we think "Brand Name" = Expensive and "Generic" = Cheap. But the data showed it's not that simple.

• The Analogy: Imagine two people selling identical apples. One calls them "Red Delicious" (Brand) and the other just calls them "Apples" (Generic). You'd expect the "Red Delicious" to cost more.
• The Twist: Sometimes the "Generic" apples were actually more expensive than the "Brand" ones!
• The Lesson: It's not just about the name on the box. It's about who is selling it and how they are selling it. Sometimes a "Generic" product comes from a supplier who charges more because they have a special deal or a specific reputation, while a "Brand" product might be on a clearance sale. The market is messy, not a straight line.

5. The "Country of Origin" Lottery

Where the medicine comes from matters a lot, but not in the way you might think.

• The Analogy: Think of the suppliers as different airlines. Flying from India is usually the "budget airline" (cheaper), while flying from Germany or the UK is the "luxury airline" (more expensive).
• The Finding: However, even within the "budget airline" (India), prices varied wildly. Sometimes the budget airline charged $50, and other times $200 for the same seat. This proves that where a medicine comes from isn't the only thing that sets the price; it's also about the specific deal the buyer made with that specific supplier at that specific time.

6. The "Rollercoaster" of Time

If you bought the same antibiotic in 2010, 2013, and 2016, the price wasn't a smooth, straight line.

• The Analogy: It was less like a slow, steady elevator going down, and more like a rollercoaster. Prices would drop, then suddenly spike, then drop again.
• The Reason: This happens because the market isn't perfectly organized. If a big supplier stops shipping for a few months, prices jump. If a new supplier enters the market, prices crash. It's a bit like a stock market that is very sensitive to who is showing up to sell.

The Big Takeaway

The main conclusion of this paper is that antibiotic prices in Tanzania are not random; they are a reflection of a complex, fragmented market.

• It's not just about the medicine: The price depends on whether it's a pill or an injection, who made it, what name is on the box, and which country it came from.
• The "Upstream" Signal: By watching these import receipts, the government can see trouble coming before it hits the pharmacy. If import prices are jumping around wildly, it means the supply chain is unstable, which could mean hospitals might run out of medicine or have to pay too much.

In short: To fix the cost of medicine, you can't just tell pharmacies to lower their prices. You have to understand the chaotic, bumpy ride of the import market first. If you smooth out the rollercoaster at the "factory gate," the prices at the "pharmacy shelf" will finally become stable and affordable for everyone.

Technical Summary

1. Problem Statement

• Context: In Low- and Middle-Income Countries (LMICs) like Tanzania, access to affordable essential medicines, particularly antibiotics, is a critical public health challenge. Domestic manufacturing capacity is limited, making these nations heavily dependent on imported pharmaceuticals.
• Knowledge Gap: While previous studies have focused on medicine availability, utilization, and retail-level affordability, there is a scarcity of longitudinal empirical evidence regarding upstream price formation. Specifically, little is known about how antibiotic prices behave at the point of market entry (importation) before distribution markups and retail pricing occur.
• Objective: The study aims to characterize the patterns and determinants of systemic antibiotic pricing in Tanzania using national regulatory data to understand market structure, supplier influence, and price variability.

2. Methodology

• Study Design: A retrospective descriptive analysis of national administrative data.
• Data Source: Import permit records from the Tanzania Medicines and Medical Devices Authority (TMDA) covering the period January 2010 to December 2016.
• Inclusion Criteria:
  • Systemic antibacterials for human use (ATC code J01).
  • Administered via oral or parenteral routes.
  • Valid unit prices (USD) greater than zero.
  • Complete data for standardization.
  • Exclusions: Topical preparations, veterinary products, and records with missing/zero prices.
• Data Processing:
  • Standardization: Prices were converted to USD per smallest unit of measure (UOM) using year-specific exchange rates.
  • Classification: Medicines were categorized by INN (International Nonproprietary Name) vs. Brand name, route of administration, dosage form, and supplier country (grouped into India, China, Germany, UK, and Others).
  • Statistical Approach: Due to highly right-skewed price distributions, non-parametric methods were used.
    • Descriptive: Median, Interquartile Range (IQR), and Min-Max ranges.
    • Inferential: Mann-Whitney U tests (comparing INN vs. Brand) and Kruskal-Wallis tests (comparing supplier countries).
    • Correction: Benjamini-Hochberg False Discovery Rate (FDR) adjustment was applied for multiple hypothesis testing.
• Software: R statistical environment (version 4.2).

3. Key Results

• Dataset Overview: From 14,301 initial records, 10,666 met inclusion criteria.

  • Formulation: Oral antibiotics dominated (89.4%), while parenteral accounted for 10.6%.
  • Therapeutic Classes: Beta-lactam penicillins were the most frequent (49.1%), followed by other beta-lactams (15.6%) and macrolides (13.0%).
  • Top Medicines: Amoxicillin-clavulanate (17.1%) and Amoxicillin (12.4%) comprised nearly one-third of all imports.
  • Supplier Origin: India was the dominant supplier (44.4%), followed by a heterogeneous group of "Other" countries (50.5%).

• Price Trends & Dispersion:

  • Temporal Trends: Median oral prices declined modestly from USD 1.85 (2010) to USD 1.20 (2016). Parenteral prices fluctuated more wildly (USD 1.50 in 2010 to USD 0.50 in 2016).
  • Route of Administration: Parenteral antibiotics were consistently more expensive and exhibited greater price dispersion than oral formulations.
  • Price Variability: Despite median declines, substantial price dispersion persisted across all years, indicated by wide IQRs and extreme values. This suggests structural market segmentation rather than isolated outliers.

• Determinants of Price Variation:

  • Naming Practice: Significant price differences were found between INN-named and Brand-named products for specific medicines (e.g., Amoxicillin: Brand median USD 0.94 vs. INN USD 1.32; Ciprofloxacin: Brand USD 2.48 vs. INN USD 2.36).
  • Supplier Country: Prices varied significantly by origin. For Amoxicillin, products from India (USD 1.35) and China (USD 0.95) were priced higher than the "Other" group (USD 0.41).
  • Within-Medicine Volatility: Prices for the same active ingredient fluctuated episodically year-to-year without a consistent monotonic trend, indicating a lack of stable pricing equilibrium.

4. Key Contributions

• Upstream Market Insight: The study provides rare longitudinal evidence of import-level pricing, offering a view of market dynamics before retail markups distort the data.
• Identification of Structural Segmentation: It demonstrates that antibiotic pricing in Tanzania is not uniform but is segmented by formulation type, supplier origin, and product branding.
• Methodological Rigor: The use of comprehensive national regulatory data (14k+ records) and non-parametric statistical analysis allows for robust characterization of skewed price distributions often missed in facility-level surveys.
• Policy Relevance: It highlights that procurement structures and supplier participation are stronger drivers of price than manufacturing costs alone.

5. Significance and Implications

• Procurement Strategy: The findings suggest that procurement decisions in import-dependent LMICs are highly sensitive to supplier participation. Relying on a few suppliers or specific countries can lead to significant price volatility.
• Antimicrobial Stewardship (AMS): Wide price dispersion can influence prescribing behavior and access. Monitoring import prices serves as an early warning system for market conditions, allowing policymakers to intervene before affordability crises reach the patient level.
• Regulatory Policy: The study supports the need for evidence-informed pricing regulations and centralized procurement strategies to reduce market fragmentation and stabilize antibiotic costs.
• Generalizability: The patterns observed (supplier concentration, price dispersion, and the impact of branding) are likely applicable to other LMICs with similar import-dependent pharmaceutical systems.

Conclusion: Antibiotic import prices in Tanzania are not random; they exhibit systematic variations driven by formulation, origin, and naming. The study concludes that monitoring import-level prices is essential for effective pharmaceutical market regulation, procurement planning, and antimicrobial stewardship in resource-limited settings.